Form 4: Myriad Genetics CSO Sells Shares for Tax

Myriad Genetics' Chief Scientific Officer, Dale Muzzey, disposed of 2,019 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc. (MYGN), reported a disposition of common stock.
• The transaction involved 2,019 shares of common stock.
• These shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units.
• The shares were valued at $4.58 per share for the purpose of tax withholding.
• Following this transaction, Dale Muzzey beneficially owns 327,256 shares of common stock.
• The transaction date was March 22, 2026, with the withholding price determined by the closing price on March 20, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a standard, non-discretionary transaction related to executive compensation and tax obligations, providing no new insights into the company's operational or financial health.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the disposition of shares to cover tax withholding obligations upon the vesting of restricted stock units, are common occurrences in the biotechnology and diagnostics industry. These transactions typically do not reflect a change in management's outlook on the company's fundamentals but rather a standard component of executive compensation and tax planning.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction by an insider for tax purposes, not indicative of a change in investment sentiment.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine insider transaction for tax withholding purposes, which does not provide new fundamental information to warrant a change in investment recommendation. It is a standard part of executive compensation and does not signal any material shift in the company's prospects or valuation.

Keywords

MYRIAD GENETICS, MYGN, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting